Meta-analysis: The effect of steroids on survival and shock during sepsis depends on the dose

Annals of Internal Medicine

Volumn 141, Issue 1, 2004, Pages

  Minneci, Peter C ^a   Deans, Katherine J ^b   Banks, Steven M ^b   Eichacker, Peter Q ^b   Natanson, Charles ^b  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; BETAMETHASONE; DEXAMETHASONE; FLUDROCORTISONE; GLUCOCORTICOID; HYDROCORTISONE; HYPERTENSIVE AGENT; METHYLPREDNISOLONE;

CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORTICOSTEROID THERAPY; DOSE CALCULATION; DRUG EFFICACY; HUMAN; MAJOR CLINICAL STUDY; MEDLINE; META ANALYSIS; MORTALITY; MULTICENTER STUDY; OUTCOMES RESEARCH; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REVIEW; SEPSIS; SHOCK; SURVIVAL RATE;

EID: 3042858950     PISSN: 00034819     EISSN: None     Source Type: Journal    
DOI: 10.7326/0003-4819-141-1-200407060-00014     Document Type: Review

References (42)

1. Angus DC, Wax RS. Epidemiology of sepsis: an update. Crit Care Med. 2001;29:S109-16. [PMID: 11445744]
2. Angus DC, Linde-Zwirble WT, Lidicker J, Clermont G, Carcillo J, Pinsky MR. Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit Care Med. 2001;29:1303-10. [PMID: 11445675]
3. Cross AS, Opal SM. A new paradigm for the treatment of sepsis: is it time to consider combination therapy? Ann Intern Med. 2003;138:502-5. [PMID: 12639085]
4. Dellinger EP. Can one use biologic modifiers to prevent multiple organ dysfunction syndrome after abdominal infections? Surg Infect (Larchmt). 2000;1: 239-48. [PMID: 12594894]
5. Silver GM, Fink MP. Possible roles for anti- or pro-inflammatory therapies in the management of sepsis. Surg Clin North Am. 1994;74:711-23. [PMID: 7515196]
6. Natanson C, Hoffman WD, Suffredini AF, Eichacker PQ, Danner RL. Selected treatment strategies for septic shock based on proposed mechanisms of pathogenesis. Ann Intern Med. 1994;120:771-83. [PMID: 8147551]
7. Zeni F, Freeman B, Natanson C. Anti-inflammatory therapies to treat sepsis and septic shock: a reassessment [Editorial]. Crit Care Med. 1997;25:1095-100. [PMID: 9233726]
8. Opal SM, Yu RL Jr. Antiendotoxin strategies for the prevention and treatment of septic shock. New approaches and future directions. Drugs. 1998;55:497-508. [PMID: 9561340]
9. Opal SM, Glück T. Endotoxin as a drug target. Crit Care Med. 2003; 31:S57-64. [PMID: 12544978]
10. Minneci P, Deans K, Natanson C, Eichacker PQ. Increasing the efficacy of anti-inflammatory agents used in the treatment of sepsis. Eur J Clin Microbiol Infect Dis. 2003;22:1-9. [PMID: 12582737]
11. Hinshaw LB, Solomon LA, Freeny PC, Reins DA. Endotoxin shock. Hemodynamic and survival effects of methylprednisolone. Arch Surg. 1967;94:61-6. [PMID: 5334743]
12. Hinshaw LB, Coalson JJ, Benjamin BA, Archer LT, Beller BK, Kling OR, et al. Escherichia coli shock in the baboon and the response to adrenocorticosteroid treatment. Surg Gynecol Obstet. 1978;147:545-57. [PMID: 100890]
13. Pingleton WW, Coalson JJ, Hinshaw LB, Guenter CA. Effects of steroid pretreatment on development of shock lung. Hemodynamic, respiratory, and morphologic studies. Lab Invest. 1972;27:445-56. [PMID: 4631792]
14. Lefering R, Neugebauer EA. Steroid controversy in sepsis and septic shock: a meta-analysis. Crit Care Med. 1995;23:1294-303. [PMID: 7600840]
15. Cronin L, Cook DJ, Carlet J, Heyland DK, King D, Lansang MA, et al. Corticosteroid treatment for sepsis: a critical appraisal and meta-analysis of the literature. Crit Care Med. 1995;23:1430-9. [PMID: 7634816]
16. Schumer W. Steroids in the treatment of clinical septic shock. Ann Surg. 1976;184:333-41. [PMID: 786190]
17. Klastersky J, Cappel R, Debusscher L. Effectiveness of betamethasone in management of severe infections. A double-blind study. N Engl J Med. 1971; 284:1248-50. [PMID: 4929896]
18. Sprung CL, Caralis PV, Marcial EH, Pierce M, Gelbard MA, Long WM, et al. The effects of high-dose corticosteroids in patients with septic shock. A prospective, controlled study. N Engl J Med. 1984;311:1137-43. [PMID: 6384785]
19. Bone RC, Fisher CJ Jr, Clemmer TP, Slotman GJ, Metz CA, Balk RA. A controlled clinical trial of high-dose methylprednisolone in the treatment of severe sepsis and septic shock. N Engl J Med. 1987;317:653-8. [PMID: 3306374]
20. Briegel J, Schelling G, Haller M, Mraz W, Forst H, Peter K. A comparison of the adrenocortical response during septic shock and after complete recovery. Intensive Care Med. 1996;22:894-9. [PMID: 8905423]
21. Annane D, Sébille V, Troché G, Raphaël JC, Gajdos P, Bellissant E. A 3-level prognostic classification in septic shock based on cortisol levels and cortisol response to corticotropin. JAMA. 2000;283:1038-45. [PMID: 10697064]
22. Pogue J, Yusuf S. Overcoming the limitations of current meta-analysis of randomised controlled trials. Lancet. 1998;351:47-52. [PMID: 9433436]
23. American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference: definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Crit Care Med. 1992;20:864-74. [PMID: 1597042]
24. Garber EK, Targoff C, Paulus HE. Glucocorticoid preparations. In: Paulus HE, Furst DE, Droomgoole SH, eds. Drugs for Rheumatic Diseases. New York: Churchill Livingstone; 1987:446.
25. Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst. 1959;22:719-48. [PMID: 13655060]
26. Breslow NE, Day NE. Statistical methods in cancer research. Volume I-The analysis of case-control studies. IARC Sci Publ. 1980:5-338. [PMID: 7216345]
27. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327:557-60. [PMID: 12958120]
28. Cochran WG. Some methods for strengthening the commom chi-square test. Biometrics. 1954;10:417-51.
29. Eichacker PQ, Parent C, Kalil A, Esposito C, Cui X, Banks SM, et al. Risk and the efficacy of antiinflammatory agents: retrospective and confirmatory studies of sepsis. Am J Respir Crit Care Med. 2002;166:1197-205. [PMID: 12403688]
30. Annane D, Sébille V, Charpentier C, Bollaert PE, François B, Korach JM, et al. Effect of treatment with low doses of hydrocortisone and fludrocortisone on mortality in patients with septic shock. JAMA. 2002;288:862-71. [PMID: 12186604]
31. Bollaert PE, Charpentier C, Levy B, Debouverie M, Audibert G, Larcan A. Reversal of late septic shock with supraphysiologic doses of hydrocortisone. Crit Care Med. 1998;26:645-50. [PMID: 9559600]
32. Briegel J, Forst H, Haller M, Schelling G, Kilger E, Kuprat G, et al. Stress doses of hydrocortisone reverse hyperdynamic septic shock: a prospective, randomized, double-blind, single-center study. Crit Care Med. 1999;27:723-32. [PMID: 10321661]
33. Chawla K, Kupfer Y, Goldman I. Hydrocorticsone reverses refractory septic shock [Abstract]. Crit Care Med. 1999;27(1 Suppl):A33.
34. Yildiz O, Doganay M, Aygen B, Güven M, Keleûtimur F, Tutufi A. Physiological-dose steroid therapy in sepsis [ISRCTN36253388]. Crit Care. 2002;6: 251-9. [PMID: 12133187]
35. Bennett IL, Finland M, Hamburger M, Kass EH, Lepper M, Waisbren BA. The effectiveness of hydrocortisone in the management of severe infection. JAMA. 1963;183:462-5.
36. Thompson WL, Gurley HT, Lutz BA, Jackson DL, Kyols LK, Morris IA. Inefficacy of glucocorticoids in shock (double-blind study) [Abstract]. Clin Res. 1976;24:258A.
37. Lucas CE, Ledgerwood AM. The cardiopulmonary response to massive doses of steroids in patients with septic shock. Arch Surg. 1984;119:537-41. [PMID: 6712466]
38. Effect of high-dose glucocorticoid therapy on mortality in patients with clinical signs of systemic sepsis. The Veterans Administration Systemic Sepsis Cooperative Study Group. N Engl J Med. 1987;317:659-65. [PMID: 2888017]
39. Luce JM, Montgomery AB, Marks JD, Turner J, Metz CA, Murray JF. Ineffectiveness of high-dose methylprednisolone in preventing parenchymal lung injury and improving mortality in patients with septic shock. Am Rev Respir Dis. 1988;138:62-8. [PMID: 3202402]
40. Lipsey MW, Wilson DB. The way in which intervention studies have "personality" and why it is important to meta-analysis. Eval Health Prof. 2001;24: 236-54. [PMID: 11523317]
41. Bernard GR, Vincent JL, Laterre PF, LaRosa SP, Dhainaut JF, Lopez-Rodriguez A, et al. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med. 2001;344:699-709. [PMID: 11236773]
42. Xigris. Drotrecogin alfa (activated) [Package insert]. Indianapolis, IN: Eli Lilly; 2002.